Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.
21 août 2024 07h00 HE
|
Pharmazz, Inc.
Pharmazz Inc. and Sun Pharma entered into an agreement under which Sun Pharma will invest up to $15 Million in Pharmazz, Inc.
Bioxodes annonce la recommandation positive du DMC pour son essai de phase 2a dans le traitement des AVC hémorragiques avec BIOX-101
21 août 2024 02h30 HE
|
Bioxodes
Le Comité de surveillance des données (DMC, Data Monitoring Committee) a recommandé la poursuite de l’étude après l’examen planifié des données provenant des 8 premiers patients L’analyse des...
Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke
21 août 2024 02h30 HE
|
Bioxodes
Planned Data Monitoring Committee (DMC) meeting recommended continuation of the study after reviewing data from the first 8 patients Interim data from 16 patients scheduled around the end of 2024 ...
Bioxodes franchit une première étape dans le recrutement de patients pour son essai de phase 2a dans le traitement des hémorragies intracérébrales avec BIOX-101
27 juin 2024 02h30 HE
|
Bioxodes
Candidat médicament « first-in-class » évalué chez les huit premiers patients Gosselies (Belgique), le 27 juin 2024 – Bioxodes SA, société biopharmaceutique en phase clinique développant de...
Bioxodes meets first Phase 2a patient enrollment milestone with BIOX-101 in intracerebral hemorrhagic stroke
27 juin 2024 02h30 HE
|
Bioxodes
First-in-class drug candidate evaluated in first eight patients Gosselies (Belgium), June 27, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for...
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of healthcare AI
25 juin 2024 09h00 HE
|
Qure.ai Technologies Limited
Qure.ai announces strategic investment by Merck Global Health Innovation Fund to boost innovation of healthcare AI.
Anthos Therapeutics Announces ~84% of Eligible Patients Have Transitioned to Abelacimab in the AZALEA-TIMI 71 Extension Study of Atrial Fibrillation Patients at a Moderate-to-High Risk of Stroke
06 juin 2024 08h15 HE
|
Anthos Therapeutics
75% of patients in the rivaroxaban arm voluntarily switched from the once-daily oral anticoagulant to once-monthly abelacimab Landmark AZALEA-TIMI 71 Study previously stopped early due to an...
L'Office européen des brevets notifie Bioxodes de son intention de délivrer un brevet offrant une large protection à son actif principal dans le traitement des thrombo-inflammations
16 mai 2024 03h04 HE
|
Bioxodes
Gosselies (Belgique), le 16 mai 2024 – Bioxodes SA, société biopharmaceutique de stade clinique développant de nouvelles thérapies dédiées à la prévention et au traitement de maladies thrombotiques et...
Bioxodes receives European Patent Office intention to grant patent, offering lead asset broad protection in thromboinflammation
16 mai 2024 03h04 HE
|
Bioxodes
Gosselies (Belgium), May 16, 2024 – Bioxodes SA, a clinical stage biopharmaceutical company developing novel therapies for the prevention and treatment of thrombotic and inflammatory diseases,...
UMeWorld to Debut the World's First & Only Weight Loss Cooking Oil in the US
09 avr. 2024 08h00 HE
|
UMeWorld Limited
MIAMI, April 09, 2024 (GLOBE NEWSWIRE) -- UMeWorld Limited (OTC: UMEWF) is excited to announce that the company has secured an exclusive license to use proprietary enzymatic technologies to...